New Formulation APPROVED of COPAXONE® Offers Patients and Their Physicians Ability to Dose Less Frequently

JERUSALEM–(BUSINESS WIRE)–Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today that the U.S. Food and Drug Administration (FDA) has approved the Company’s supplemental new drug application (sNDA) for three-times-a-week COPAXONE® 40mg/mL, a new dose of COPAXONE®. This new formulation will allow for a less frequent dosing regimen administered subcutaneously for patients with relapsing forms of multiple sclerosis (MS). In addition to the newly approved dose, daily COPAXONE® 20 mg/mL will continue to be available. The daily subcutaneous injection was approved in 1996.


Continue

……..

To comment – click the comment link shown below
…….
Share our Articles with others

……
Sign-up at:  www.msviewsandnews.org 
To Keep CURRENT  and up to date with MS News and Information

 ————-

Donate Now Please – Click here

Thank you    

…………………….

.